Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cellebrite DI (CLBT) EBITDA: 2020-2025

Historic EBITDA for Cellebrite DI (CLBT) over the last 5 years, with Sep 2025 value amounting to $20.0 million.

  • Cellebrite DI's EBITDA fell 90.38% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.4 million, marking a year-over-year decrease of 75.27%. This contributed to the annual value of $282.0 million for FY2024, which is 250.79% up from last year.
  • Cellebrite DI's EBITDA amounted to $20.0 million in Q3 2025, which was down 5.73% from $21.2 million recorded in Q2 2025.
  • In the past 5 years, Cellebrite DI's EBITDA ranged from a high of $207.9 million in Q3 2024 and a low of $1.9 million during Q1 2022.
  • Over the past 3 years, Cellebrite DI's median EBITDA value was $21.2 million (recorded in 2025), while the average stood at $43.3 million.
  • Per our database at Business Quant, Cellebrite DI's EBITDA spiked by 2,719.35% in 2024 and then crashed by 90.38% in 2025.
  • Quarterly analysis of 5 years shows Cellebrite DI's EBITDA stood at $4.3 million in 2021, then spiked by 90.04% to $8.2 million in 2022, then surged by 70.95% to $14.0 million in 2023, then surged by 49.68% to $20.9 million in 2024, then plummeted by 90.38% to $20.0 million in 2025.
  • Its EBITDA was $20.0 million in Q3 2025, compared to $21.2 million in Q2 2025 and $16.2 million in Q1 2025.